Dr. Shimon Eckhouse News
2 articles
growth-positive
Shimon Eckhouse brings Epitomee Medical to TASE
Epitomee, a company founded by Dr. Shimon Eckhouse, has successfully floated on the Tel Aviv Stock Exchange. The company has developed an ingestible pill for treating obesity and delivering drugs to the stomach. Epitomee raised NIS 162 million at a valuation of NIS 632 million, with Nestlé converting a $7 million loan to equity. The pill expands in the stomach, creating a sensation of fullness, and disintegrates within a few hours. Epitomee has a marketing agreement with Nestlé Health Science, entitling it to receive $115 million in advance and milestone payments. The company plans to start commercial production and sales in early 2023. Epitomees main shareholders include Dr. Shimon Eckhouse, Chinese fund Star Concept, and companies owned by Idan Ofer and Udi Angel.
InvestmentPartners
growth-positive
Shimon Eckhouse rides again with SofWave
SofWave Medical, an aesthetic medicine company founded by Shimon Eckhouse, has been listed on the Tel Aviv Stock Exchange (TASE). The company has developed an anti-aging product for skin tightening using new ultrasound technology. Despite the challenges of launching the product during the COVID-19 pandemic, SofWave Medical has achieved successful market penetration. In the first half of 2021, the company generated $10.2 million in revenue with a gross margin of 73.8%. SofWave Medical raised NIS 160 million in its IPO at a valuation of NIS 800 million. The companys share price is currently close to the issue price. The CEO, Eckhouse, is confident in the companys potential for rapid growth and its ability to prove itself in the market.
Public TradingInvestment
